This was a very hectic week in the market, with major swings in the indexes and in our universe of smaller companies. Earnings season for most smaller companies is the first two weeks of August, which creates ample reasons...
MEDFORD, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2019. Recent Accomplishments & Highlights Achieved total revenue of $9.6 million for the second quarter...
MEDFORD, N.Y., May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in...
MEDFORD, N.Y., May 01, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2019. Recent Accomplishments & Highlights Achieved total revenue of $8.3 million for the first quarter...
Tailwinds' Take: continued execution demonstrates their unique ability to create multiplex diagnostics. MEDFORD, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by...
MEDFORD, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development of a diagnostic...
Tailwinds' Take: a small beat, as expected. Margins low, but due primarily to investing in growth, so like that answer. Longer term targets for 2023 reflect strong growth and very bullish. Management is competent and confident. All good here. MEDFORD,...
Tailwinds' Take: good news and incremental to their guidance.  MEDFORD, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that it will be awarded a conditional Long Term Arrangement (LTA) from UNICEF for purchases of the company’s...
Tailwinds' Take: solid guidance for the Q is well ahead of street forecasts.  MEDFORD, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today preliminary estimates of revenue for the fourth...
MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host an analyst and institutional investor meeting on Wednesday, February 6, 2019, in New York City from 8:30 a.m. to approximately 10:30...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.